(Q37781370)

23 August 2017

title

Atypical antipsychotic tolerability and switching strategies in bipolar disorder (English)

1 reference

23 August 2017

1 reference

2

Roger S McIntyre

1 reference

23 August 2017

Samantha S Liauw

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

23 August 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

published in

1 reference

23 August 2017

volume

11

1 reference

23 August 2017

issue

17

1 reference

23 August 2017

page(s)

2827-2837

1 reference

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Obesity as a correlate of outcome in patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

The relationship between interdialytic weight gain and patient compliance. A single centred cohort study (n=21).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

An assessment of iloperidone for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

A retrospective study of clozapine and electroencephalographic abnormalities in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Neuroleptic Malignant Syndrome and Atypical Antipsychotic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Prolactin levels and adverse events in patients treated with risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Iloperidone: a new option for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.510835

10.1517/14656566.2010.510835

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference